Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate

BIOLOGICAL4 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

MeaslesMeningitisMeningococcal DiseaseMeningococcal InfectionMeningococcal MeningitisMeningococcemiaMumpsRubella

Phase 3

Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers

CompletedNCT00483574

Sanofi Pasteur, a Sanofi CompanyMeasles, Meningococcal Meningitis, Mumps +2

Start: 2007-05-31End: 2009-04-30Updated: 2016-05-16

Immunology and Safety of Menactra® in Children in Saudi Arabia

CompletedNCT00539032

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcemia

Start: 2007-09-30End: 2009-02-28Updated: 2016-04-14

Phase 4

Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines

CompletedNCT01270503

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Disease

Start: 2010-12-31End: 2014-07-31Updated: 2014-11-14

Unknown Phase

Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children

CompletedNCT01689155

Sanofi Pasteur, a Sanofi CompanyMeningitis, Meningococcal Infection

Start: 2011-06-30End: 2016-04-30Updated: 2016-11-11

Related Papers

Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children

Vaccine2018-03-1813 citations